You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
MBio is developing the system for use with human host-response biomarker assays that can be used to identify gravely ill or highly contagious individuals.
The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.
The company will use the funds to work in collaboration with George Mason University to apply its technology to detecting viruses in non-invasive samples.